Nrf2/HO-1 activator 1 (Compound 24) is a potent neuroprotective agent with significant antioxidant activities, specifically targeting Nrf2/HO-1. It is particularly useful in Parkinson's disease (PD) research, illustrating its potential in therapeutic applications [1].

Nrf2/HO-1 activator 1 (0.3-30 μM; 24 h) exhibits potent neuroprotection in both 6-OHDA- and rotenone-induced cell death models [1]. Nrf2/HO-1 activator 1 (1-30 μM; 6 h) increases HO-1 expression in PC12 cells [1]. Nrf2/HO-1 activator 1 (12 μM; 1-12 h) increases phosphorylation of ERK1/2, JNK, and Akt in PC12 cells [1]. Cell Viability Assay [1] Cell Line: PC12 cells Concentration: 0.3, 1, 3, 10, and 30 μM Incubation Time: 4 hours Result: Inhibited 6-OHDA-induced toxicity with IC 50 of 3.9 μM. Inhibited rotenone-induced toxicity with IC 50 of 4.8 μM. Western Blot Analysis [1] Cell Line: PC12 cells Concentration: 10 μM Incubation Time: 1, 3, 6, and 12 hours Result: Induced phosphorylation of ERK1/2, JNK, and Akt. Western Blot Analysis [1] Cell Line: PC12 cells Concentration: 1, 3, 10, and 30 μM Incubation Time: 6 hours Result: Increased HO-1 expression in a dose-dependent manner, with 2-fold increases at 30 μM concentrations.

Nrf2/HO-1 activator 1 inhibits the production of lipid peroxide in rat brain homogenates by 50.5% at 100 μM [1].